Synthesis of prodrug-type anti-HIV agents conjugating a REVERSE transcriptase inhibitor to a HIV-1 integrase inhibitor by a spontaneously cleavable linker

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 22, Issue 5, 2007, Pages 591-607

  Fossey, Christine ^a   Vu, Anh Hoang ^a   Vidu, Anamaria ^a   Zarafu, Irina ^a   Laduree, Daniel ^a   Schmidt, Sylvie ^b   Laumond, Geraldine ^b   Aubertin, Anne Marie ^b  

^a CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

^b INSERM   (France)

Author keywords

HIV; Integrase; Nucleoside inhibitor; Reverse transcriptase

Indexed keywords

1 (3 BENZYLOXYPHENYL)ETHANONE; 1 (3,5 DIBENZYLOXYPHENYL)ETHANONE; 1 (4 BENZYLOXYPHENYL)ETHANONE; 1 [1 (2 FLUOROBENZYL) 1H PYRROL 2 YL]ETHANONE; 1 [1 (4 FLUOROBENZYL) 1H PYRROL 2 YL]ETHANONE; 4 (3 BENZYLOXYPHENYL) 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; 4 (3 BENZYLOXYPHENYL) 2 HYDROXY 4 OXOBUT 2 ENOYL 2 AMINOPHENYLMETHANOL; 4 (3 BENZYLOXYPHENYL) 2 HYDROXY 4 OXOBUT 2 ENOYL 4 AMINOPHENYLMETHANOL; 4 (3,5 DIBENZYLOXYPHENYL) 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; 4 (3,5 DIBENZYLOXYPHENYL) 2 HYDROXY 4 OXOBUT 2 ENOYL 2 AMINOPHENYLMETHANOL; 4 (3,5 DIBENZYLOXYPHENYL) 2 HYDROXY 4 OXOBUT 2 ENOYL 4 AMINOPHENYLMETHANOL; 4 (4 BENZYLOXYPHENYL) 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; 4 (4 BENZYLOXYPHENYL) 2 HYDROXY 4 OXOBUT 2 ENOYL 2 AMINOPHENYLMETHANOL; 4 (4 BENZYLOXYPHENYL) 2 HYDROXY 4 OXOBUT 2 ENOYL 4 AMINOPHENYLMETHANOL; 4 [1 (2 FLUOROBENZYL) 1H PYRROL 2 YL] 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; 4 [1 (2 FLUOROBENZYL) 1H PYRROL 2 YL] 2 HYDROXY 4 OXOBUT 2 ENOYL 2 AMINOPHENYLMETHANOL; 4 [1 (2 FLUOROBENZYL) 1H PYRROL 2 YL] 2 HYDROXY 4 OXOBUT 2 ENOYL 4 AMINOPHENYLMETHANOL; 4 [1 (4 FLUOROBENZYL) 1H PYRROL 2 YL] 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; 4 [1 (4 FLUOROBENZYL) 1H PYRROL 2 YL] 2 HYDROXY 4 OXOBUT 2 ENOYL 2 AMINOPHENYLMETHANOL; 4 [1 (4 FLUOROBENZYL) 1H PYRROL 2 YL] 2 HYDROXY 4 OXOBUT 2 ENOYL 4 AMINOPHENYLMETHANOL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ETHYL 4 (3 BENZYLOXYPHENYL) 2 HYDROXY 4 OXOBUT 2 ENOATE; ETHYL 4 (3,5 DIBENZYLOXYPHENYL) 2 HYDROXY 4 OXOBUT 2 ENOATE; ETHYL 4 (4 BENZYLOXYPHENYL) 2 HYDROXY 4 OXOBUT 2 ENOATE; ETHYL 4 [1 (2 FLUOROBENZYL) 1H PYRROL 2 YL] 2 HYDROXY 4 OXOBUT 2 ENOATE; ETHYL 4 [1 (4 FLUOROBENZYL) 1H PYRROL 2 YL] 2 HYDROXY 4 OXOBUT 2 ENOATE; STAVUDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IC 50; NONHUMAN; PRIORITY JOURNAL;

ANTI-HIV AGENTS; CELL LINE; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; DRUG DESIGN; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PRODRUGS; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 35348990806     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360701425386     Document Type: Article

References (57)

1. De Clercq, E. (1995) J Med Chem, 38, pp. 2491-2517.
2. De Clercq, E. (2002) Nat Rev Drug Discovery, 1, pp. 13-25.
3. Imamichi, T. (2004) Curr Pharm Des, 10, pp. 4039-4053.
4. Richman, DD (2001) Nature, 410, pp. 995-1001.
5. Dayam, R. and Neamati, N. (2004) Biochemistry of HIV therapeutics. Encyclopedia of molecular cell biology and molecular medicine, pp. 155-178. Wiley-VCH, Weinheim, Germany
6. Barbaro, G., Scozzafava, A., Mastrolorenzo, A. and Supuran, CT (2005) Curr Pharm Des, 11, pp. 1805-1843.
7. Cohen, J. (2002) Science, 296, pp. 2320-2324.
8. Mocroft, A. and Lundgren, JD (2004) Antimicrob Chemother, 54, pp. 10-13.
9. Shehu-Xhilaga, M., Tachedjian, G., Crowe, SM and Kedzierska, K. (2005) Curr Med Chem, 12, pp. 1705-1719.
10. Pommier, Y. and Neamati, N. (1999) Adv Virus Res, 52, pp. 427-458.
11. Asante-Appiah, E. and Skalka, AM (1999) Adv Virus Res, 52, pp. 351-369.
12. Nair, V. (2002) Rev Med Virol, 12, pp. 179-193.
13. Hazuda, DJ and Young, SD (2004) Adv Antiviral Drug Des, 4, pp. 63-77.
14. Pommier, Y., Johnson, AA and Marchand, C. (2005) Nat Rev Drug Disc, 4, pp. 236-248.
15. Mazumder, A., Uchida, H., Neamati, N., Sunder, S., Jaworska-Maslanka, M., Wickstrom, E., Zeng, F., Jones, RA, Mandes, RF, Chenault, HK and Pommier, Y. (1997) Mol Pharmacol, 51, pp. 567-575.
16. Burke Jr, TR, Fesen, M., Mazumder, A., Yung, J., Wang, J., Carothers, AM, Grunberger, D., Driscoll, J., Pommier, Y. and Kohn, K. (1995) J Med Chem, 38, pp. 4171-4178.
17. Zhao, H., Neamati, N., Mazumder, A., Sunder, S., Pommier, Y. and Burke Jr, TR (1997) J Med Chem, 40, pp. 1186-1194.
18. Artico, M., Santo, R Di, Costi, R., Novellino, E., Greco, G., Massa, S., Tramontano, E., Marongiu, ME, De Montis, A. and La Colla, P. (1998) J Med Chem, 41, pp. 3948-3960.
19. King, PJ, Miao, W., Jia, Q., McDougall, BR, Reinecke, MG, Cornell, C., Kuan, J., Kim, TR and Robinson Jr, WE (1999) J Med Chem, 42, pp. 497-509.
20. Lin, Z., Neamati, N., Zhao, H., Kiryu, Y., Turpin, JA, Aberham, C., Strebel, K., Kohn, K., Witvrouw, M., Pannecouque, C., Debyser, Z., De Clercq, E., Rice, WG, Pommier, Y. and Burke Jr, TR (1999) J Med Chem, 42, pp. 1401-1414.
21. Goldgur, Y., Craigie, R., Cohen, GH, Fujiwara, T., Yoshinaga, T., Fujishita, T., Sugimoto, H., Endo, T., Murai, H. and Davies, DR (1999) Proc Natl Acad Sci U.S.A., 96, pp. 13040-13043.
22. Hazuda, DJ, Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, JA, Espeseth, A., Gabryelski, L., Schleif, W., Blau, C. and Miller, MD (2000) Science, 287, pp. 646-650.
23. Fujishita, T. and Yoshinaga, T. (1999) WO 9950245
24. Wai, JS, Egbertson, MS, Payne, LS, Fisher, TE, Embrey, MW, Tran, LO, Melamed, JY, Langford, HM, Guare Jr, JP, Zhuang, L., Grey, VE, Vacca, JP, Holloway, MK, Naylor-Olsen, AM, Hazuda, DJ, Felock, PJ, Wolfe, AL, Stillmock, KA, Schleif, WA, Gabryelski, LJ and Young, SD (2000) J Med Chem, 43, pp. 4923-4926.
25. Grobler, JA, Stillmock, K., Witmer, M., Felock, P., Espeseth, AS, Wolfe, A., Egbertson, M., Bourgeois, M., Melamed, J., Wai, JS, Young, S., Vacca, J. and Hazuda, DJ (2002) Proc Natl Acad Sci U.S.A., 99, pp. 6661-6666.
26. Pais, GCG, Zhang, X., Marchand, C., Neamati, N., Cowansage, K., Svarovskaia, ES, Pathak, VK, Tang, Y., Nicklaus, M., Pommier, Y. and Burke Jr, TR (2002) J Med Chem, 45, pp. 3184-3194.
27. Zhang, X., Pais, GCG, Svarovskaia, ES, Marchand, C., Johnson, AA, Karki, RG, Nicklaus, MC, Pathak, VK, Pommier, Y. and Burke, TR (2003) Bioorg Med Chem Lett, 13, pp. 1215-1219.
28. Johnson, AA, Marchand, C. and Pommier, Y. (2004) Curr Top Med Chem, 4, pp. 671-686.
29. Neamati, N. (2002) Expert Opin Ther Patents, 12, pp. 709-724.
30. Cass, CE, Young, JD and Baldwin, SA (1998) Biochem Cell Biol, 76, p. 761.
31. Ralevic, V. and Burnstock, G. (1998) Pharmacol Rev, 50, p. 413.
32. Chan, TCK, Shaffer, L., Redmond, R. and Pennington, KL (1993) Biochem Pharmacol, 46, p. 273.
33. Domin, BA, Mahony, WB and Zimmerman, TP (1993) Biochem Pharmacol, 46, p. 725.
34. Sugeac, E., Fossey, C., Ladurée, D., Schmidt, S., Laumond, G. and Aubertin, AM (2004) J Enz Inhib Med Chem, 19:6, pp. 497-509.
35. Mansuri, MM, Starrett, JE, Ghazzouli, I., Hitchcock, MJM, Sterzycki, RZ, Brankovan, V., Lin, T., August, EM, Prusoff, WH, Sommadossi, J. and Martin, JC (1989) J Med Chem, 32, pp. 461-466.
36. Shiragami, H., Uchida, Y. and Izaw, K. (1996) Nucleosides & Nucleotides, 15, pp. 47-58.
37. Lin, T., Schinazi, RF and Prusoff, WH (1987) Biochem Pharmacol, 36, pp. 2713-2718.
38. Balzarini, J., Kang, GJ, Dalal, M., Herdewijn, P., De Clercq, E. and Broder, Johns DG (1987) Mol Pharmacol, 32, pp. 162-167.
39. Browne, MJ, Mayer, KH, Chafee, SB, Dudley, MN, Posner, MR, Steinberg, SM, Graham, KK, Geletko, SM, Zinner, SH, Denman, SL, Dunkle, LM, Kaul, S., Laren, C Mc, Skowron, G., Kontlab, NM, Kennedy, TA, Weitberg, AB and Curt, GA (1993) J Infect Dis, 167, pp. 21-29.
40. Carl, PL, Chakravarty, PK and Katzenellenbogen, JA (1981) J Med Chem, 24, pp. 479-480.
41. De Groot, FMH, de Bart, ACW, Verheijen, JH and Scheeren, HW (1999) J Med Chem, 42, pp. 5277-5283.
42. De Groot, FMH, van Berkom, LWA and Scheeren, HW (2000) J Med Chem, 43, pp. 3093-3102.
43. De Groot, FMH, Loos, WJ, Koekkoek, R., van Berkom, LWA, Busscher, GF, Seelen, AE, Albrecht, C., de Bruijn, P. and Scheeren, HW (2001) J Org Chem, 66, pp. 8815-8830.
44. Florent, J-C, Dong, X., Gaudel, G., Mitaku, S., Monneret, C., Gesson, J-P, Jacquesy, J-C, Mondon, M., Renoux, B., Andrianomenjanahary, S., Michel, S., Koch, M., Tillequin, F., Gerken, M., Czech, J., Straub, R. and Bosslet, K. (1998) J Med Chem, 41, pp. 3572-3581.
45. Bouvier, E., Thirot, S., Schmidt, F. and Monneret, C. (2004) Biorgan & Med Chem, 12, pp. 969-977.
46. Alaoui, A El, Saha, N., Schmidt, F., Monneret, C. and Florent, J-C (2006) Biorgan Med Chem, 14, pp. 5012-5019.
47. Jeffrey, SC, Torgov, MY, Andreyka, JB, Boddington, L., Cerveny, CG, Denny, WA, Gordon, KA, Gustin, D., Haugen, J., Kline, T., Nuyen, MT and Senter, PD (2005) J Med Chem, 48, pp. 1344-1358.
48. Walker, MA, King, HD, Dalterio, RA, Trail, P., Firestone, R. and Dubowchik, GM (2004) Biorgan Med Chem, 14, pp. 4323-4327.
49. Hay, MP, Wilson, WR and Denny, WA (2005) Biorgan Med Chem, 13, pp. 4043-4055.
50. Moog, C., Wick, A., Ber, P Le, Kirn, A. and Aubertin, AM (1994) Antiviral Res, 24, pp. 275-288.
51. Chou, J. and Chou, TC Computer software for Apple II Series and IBM-PC and instruction manual, pp. 19-28. Elsevier-Biosoft, Cambridge
52. Mosmann, T. (1983) J Immunol Meth, 65, pp. 55-63.
53. Lefebvre, I., Perigaud, C., Pompon, A., Aubertin, AM, Girardet, JL, Kirn, A., Gosselin, G. and Imbach, JL (1995) J Med Chem, 38, pp. 3941-3950.
54. Joshi, BV, Rao, TS and Reese, CB (1992) J Chem Soc Perkin Trans, pp. 2537-2544.
55. Belleau, B. and Malek, GA (1968) J Am Chem Soc, 90, pp. 1651-1652.
56. Hay, MP, Wilson, WR and Denny, WA (2000) Tetrahedron, 56:4, pp. 645-657.
57. Meier, C. (1998) Synlett, 3, pp. 233-242.